Amwill Healthcare's stock market debut on February 12, 2025, saw a weaker than expected performance, with shares listed at ₹89 apiece, reflecting a 20% discount on the initial offer price of ₹111. This was a significant moment for the company, which had raised ₹59.97 crores through its Book Built Issue. The issue consisted of 44.03 lakh shares in a fresh issue, along with an offer for sale of 10 lakh shares.

The company, which focuses on dermatology, trichology, and cosmetology, is one of the fastest-growing entities in India in the dermatology space. Amwill Healthcare's products are based on high-tech, advanced active cosmetology and dermatology, combining natural ingredients, allopathic actives, and special techniques. Despite the subdued debut, Amwill Healthcare has shown robust financial growth in recent years, suggesting a promising future.

The IPO price range was set between ₹105 and ₹111 per share, with a market capitalization of ₹222.04 crores at the upper price band. However, the grey market premium (GMP) for the shares was ₹0, indicating minimal demand in the unregulated market. The share allotment period closed on February 7, 2025, and the listing took place on February 12, with investors eagerly watching the market response.

In terms of financial performance, Amwill Healthcare reported steady growth, with revenues of ₹2,324.71 lakh for the period ending September 30, 2024, and a profit after tax of ₹651.66 lakh for the same period. The company has managed to maintain strong EBITDA margins, indicating efficient operations. These figures reflect an upward trend in profitability, making the company's valuation at the IPO fully priced with a P/E ratio of 13.81x.

The financials also highlight strong return on equity (ROE) and return on capital employed (ROCE) figures of 73.06% and 94.16%, respectively, for FY24, suggesting efficient utilization of capital. The IPO review suggests that while the listing did not meet investor expectations, Amwill Healthcare remains a leader in its niche segment, and its growth trajectory remains promising.

Key Objectives of the Amwill Healthcare IPO include utilizing the net proceeds to fund working capital, brand-building activities, and general corporate purposes. With a focus on marketing and expansion, the company aims to strengthen its presence in the dermatology and cosmetology sectors, driving future growth.

While the initial listing performance has been disappointing, Amwill Healthcare's strong business fundamentals and industry leadership indicate that the long-term prospects for the company remain promising. The company’s promoters, Tarun Gandhi and Anand Gandhi, have a long track record in the dermatological and pharmaceutical industry, which further solidifies confidence in their ability to drive the company's growth.

In conclusion, while Amwill Healthcare's IPO debut might not have been as strong as expected, the company's continued focus on expanding its market share in dermatology and cosmetology should position it well for long-term success. Investors are advised to keep an eye on the company's future performance and the impact of its strategic marketing and expansion efforts in the coming quarters.

The Upcoming IPOs in this week and coming weeks are Quality Power Electrical Equipmwnt, PS Raj Steels, Voler Car, Maxvolt Energy, Hexaware Technologies, L.K. Mehta, Shanmuga Hospital.

The Current active IPO are Ajax Engineering, Chandan Healthcare..

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.

Join our Finance Saathi Telegram Channel for Regular Share Market, News & IPO Updates.